P4, N=2500, Recruiting, Duke University | Trial completion date: Apr 2026 --> Oct 2026

P=N/A, N=15, Recruiting, The First Hospital of China Medical University; The First Hospital of China Medical University

P4, N=600, Recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

P4, N=316, Recruiting, Affiliated Hospital of Yangzhou University; Affiliated Hospital of Yangzhou University

P1, N=382, Completed, Taro Pharmaceuticals USA

Serum levels of interleukin-6, interleukin-8, tumor necrosis factor-α, and procalcitonin were significantly lower in the study group compared to the control group (all P < .05). The use of CAM combined with FP in patients after FESS for CRS is effective, leading to the relief of clinical symptoms, improvement of nasal function, enhancement of MCT function, and reduction of inflammatory response, without increasing the incidence of adverse reactions.

P3, N=865, Recruiting, MicuRx | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026

P1, N=72, Recruiting, Wake Forest University Health Sciences | Not yet recruiting --> Recruiting

This review discusses several potent alkaloids, such as homoharringtonine, chaetominine, matrine, and jerantinine B, which induce apoptosis, cell cycle arrest, and autophagy and inhibit signaling pathways including PI3K/Akt/mTOR, MAPK, and NF-κB...In addition, targeting leukemia stem cells (LSCs) with alkaloids such as zalypsis offers promise due to its ability to induce apoptosis without significantly affecting normal hematopoietic stem cells...For example, jerantinine B targets AML cells, while vincristine has shown success in lymphocytic leukemia...However, adverse effects such as neutropenia and hepatotoxicity necessitate careful management. Collectively, these findings emphasize the need for further research into alkaloid-based combination therapies to enhance efficacy and minimize toxicity, providing a promising avenue for innovative leukemia treatments.

P2, N=99, Recruiting, Insel Gruppe AG, University Hospital Bern | Not yet recruiting --> Recruiting

P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=52 --> 0 | Trial completion date: Jul 2030 --> Oct 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2028 --> Oct 2024

Taken together, our results confirm that HHT is a substrate for MDR1. It opens the door to a new opportunity to clinically evaluate HHT and its derivatives for the treatment of AML and other cancers.

The antibacterial activity against Staphylococcus aureus and Klebsiella pneumoniae showed the maximum zone of inhibition at 250 μg/mL in comparison with gentamicin...The mechanism of action of GM-AgNPs confirmed the initiation of apoptosis and cell cycle arrest in the sub-G0/G1 (growth phase) phase by 48.19%. In gene expression and protein expression analyses, Bax and Bcl-2 were altered to those of normal physiology.

Long-term SNL therapy also restored mitochondrial electron transport chain complex enzymes, such as complex-I (p < .001). In conclusion, these findings suggest that SNL can represent a protective therapeutic option for drug-induced nephrotoxicity, a long-term adverse effect of aminoglycoside antibiotics such as gentamicin.

P2/3, N=28, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Sponsor decision

Gentamicin reduced miR-182-5p levels and increased cochlear oxidative stress and cell death in mice - an effect that was corrected by inner ear stem cell-derived exosomes. There is ongoing work seeking to determine if these findings can be effectively translated to humans.

P1/2, N=24, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Sep 2024 | Trial primary completion date: Aug 2025 --> Sep 2024

P4, N=1770, Active, not recruiting, Duke University | Recruiting --> Active, not recruiting | N=8000 --> 1770 | Trial completion date: Oct 2024 --> Aug 2025

P4, N=548, Recruiting, Xijing Hospital of Digestive Diseases

P=N/A, N=10, Recruiting, Mayo Clinic

P2, N=309, Active, not recruiting, Global Alliance for TB Drug Development | Recruiting --> Active, not recruiting

P=N/A, N=2000, Not yet recruiting, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Jiangsu Pharmaceutical Association

P1, N=546, Not yet recruiting, Shenzhen Hospital of Southern Medical University; Jiangsu?Wanbang?Pharmaceutical?Marketing?& Distribution?Co.,Ltd

P2, N=26, Completed, Global Alliance for TB Drug Development | Active, not recruiting --> Completed

P2/3, N=855, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

The formation of the HIF-1α/ERβ/E2F1 feedforward loop promotes NSCLC growth and reveals a novel molecular mechanism by which HHT induces cell death in NSCLC.

In this study, we observed that combining homoharringtonine (HHT) with VEN plus azacitidine resulted in a significantly higher response and better survival than VA alone in patients with R/R-AML. Mechanistically, HHT sensitizes AML cells to VEN by downregulating the anti-apoptotic proteins MCL-1/BCL-xL, activating reactive oxygen species (ROS), leading to mitochondrial membrane potential loss, and attenuating fatty acid (FA) uptake. These findings adding HHT to VEN-based regimens may enhance outcomes in R/R-AML patients.

P2, N=26, Not yet recruiting, University Hospital, Toulouse | Initiation date: Apr 2024 --> Sep 2024

Inhibiting FOXM1 pharmacologically with thiostrepton produced tumor-suppressive effects and improved immunotherapy responses in a Lewis lung carcinoma mouse model. The senescence-related signature demonstrates potential in predicting patient prognosis and immunotherapy efficacy in LUAD.

P=N/A, N=40, Recruiting, Semmelweis University | Not yet recruiting --> Recruiting

P3, N=100, Recruiting, University Hospital, Toulouse | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025

P=N/A, N=148, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting

P4, N=1600, Recruiting, Carilion Clinic | Trial completion date: Sep 2022 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Sep 2026

These results suggest that, in addition to inhibiting FoxM1, TST may induce proteotoxicity and autophagy to disrupt cellular tubulin polymerization, and this mechanism might account for its antimitotic effects, enhancement of Taxol anticancer effects, and ability to overcome Taxol resistance in MDA-MB-231 cells. These data further imply that TST may be useful to improve the therapeutic efficacy of Taxol.

P2, N=20, Recruiting, LigaChem Biosciences, Inc. | Active, not recruiting --> Recruiting

P4, N=200, Recruiting, Shanghai Jiao Tong University School of Medicine

P4, N=476, Recruiting, Shanghai Jiao Tong University School of Medicine

Our findings demonstrate that a combination of HHT/VEN is effective on ETP-ALL and represents the "backbone" of a promising and safe regimen for newly diagnosed and R/R patients with ETP-ALL.

P3, N=1100, Recruiting, Balgrist University Hospital | N=414 --> 1100 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024

Despite attenuation of IL-8, minocycline did not alter self-reported affective symptoms or cognition in this cohort of BC survivors undergoing chemotherapy. The effect of minocycline on BC survivors symptomatic for depression before chemotherapy warrants further investigation.

Correlations were significantly negative between BDNF and MDA, NO, TNF-α, COX 2, and caspase-3 immunoreaction and significantly positive with CAT, HO-1, and PCNA immunoreaction. EZE can safeguard inner ear tissues from GM via antioxidant, anti-inflammatory, and antiapoptotic mechanisms, as well as upregulation of BDNF mechanisms.

P1, N=20, Not yet recruiting, University of Bologna